Clinical Trial VICCRAD1060


A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients with 1-4 Brain Metastases

Principal Investigator(s)

Bapsi Chak


  • Protocol No. VICCRAD1060
  • Open Date: 02/15/2011
  • Staging: Phase I
  • Age Group: Adults
  • Scope: Local
  • Objective: To determine the safety, tolerability and maximum tolerated dose (MTD) of sorafenib, when administered in combination with SRS to patients with 1-4 metastatic brain tumors.
  • Disease Sites: Neuro-Oncology
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy
  • Drugs: BAY 43-9006 (Sorafenib); Sorafenib (Nexavar)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01276210
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.